Details of the Drug Combinations

General Information of This Drug (ID: DMBSHMF)

Drug Name

BOCEPREVIR DMBSHMF

Synonyms

Boceprevir; Victrelis; 394730-60-0; SCH 503034; EBP 520; UNII-89BT58KELH; SCH-503034; 89BT58KELH; CHEBI:68621; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Boceprevir + Dolutegravir	DCB3X98	Dolutegravir	Infection, Human Immunodeficiency Virus	[3]
Boceprevir + Raltegravir	DCUAY9A	Raltegravir	HIV Infections	[4]
Boceprevir + Simeprevir	DC334QN	Simeprevir	Chronic Hepatitis C Infection	[5]
Omeprazole + Boceprevir	DCQOHU2	Omeprazole	HCV Infections	[6]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7876).
2	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. 2020. April 20. doi: https://doi.org/10.1101/2020.04.20.051581
3	ClinicalTrials.gov (NCT01563328) A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).
4	ClinicalTrials.gov (NCT01288417) Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
5	ClinicalTrials.gov (NCT02333292) Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
6	ClinicalTrials.gov (NCT01470690) Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)